Health · 1 sources covering this

STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/875eed957d5ed8f2c3b088afd64410b3cca60579"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss"></iframe>

STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

How 1 sources are covering this

STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

More from Health

STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe

U.S. officials declare an end to record-setting cyclospora outbreak, but its origin is still unknown

As diseases loom, CDC's response to measles deaths stirs fears about agency's reliability

STAT+: Up and down the ladder: The latest comings and goings

Reader

Trust & legal

Across the network